References

emcardio

Неотложная кардиология и кардиоваскулярные риски

Emergency Cardiology and Cardiovascular Risks journal

2616-633X

Белорусский государственный медицинский университет

10.51922/2616-633X.2023.7.2.1991

emcardio-26

Research Article

Обзоры и лекции

Reviews and lectures

Неалкогольная жировая болезнь печени и кардиоваскулярные риски

Non-alcoholic fatty liver disease and cardiovascular risks

Антюх

К. Ю.

Antyukh

Минск

Minsk

Республиканский научно-практический центр «Кардиология»Republican Scientific and Practical Center of Cardiology

2023

19062025

7219911999

2025

Антюх К.Ю.

Antyukh K.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://emcardio.bsmu.by/jour/article/view/26

Неалкогольная жировая болезнь печени – это многофакторное заболевание со сложным механизмом развития, которое ассоциировано с нарушениями обмена веществ, функции различных органов и систем, а также с возникновением ряда заболеваний, в частности, атеросклероза. По данным научных исследований, проведенных в последние годы, неалкогольная жировая болезнь печени является предиктором неблагоприятных сердечно-сосудистых событий и может выступать самостоятельным фактором риска развития болезней системы кровообращения, независимо от наличия сахарного диабета, дислипидемии или ожирения. Цель настоящей работы – провести анализ опубликованных научно-исследовательских данных по эпидемиологии, этиопатогенезу, диагностике и особенностям клинического течения неалкогольной жировой болезни печени у пациентов с болезнями системы кровообращения; охарактеризовать современное состояние проблемы, определить направление проведения дальнейших исследований.

Non-alcoholic fatty liver disease is a multifactorial disease with a complicated mechanism development, which is associated with metabolic disorders, the functions of various organs and systems, as well as the occurrence of a number of diseases, in particular atherosclerosis. According to research conducted in recent years, non-alcoholic fatty liver disease is a predictor of adverse cardiovascular events and can act as an independent risk factor for the development of diseases of the circulatory system, regardless of the presence of diabetes mellitus, dyslipidemia or obesity. The purpose of this work is to analyze the published research data on the epidemiology, etiopathogenesis, diagnosis and features of the clinical course of non-alcoholic fatty liver disease in patients with diseases of the circulatory system as well as to characterize the current state of the problem and to determine the direction for further research.

неалкогольная жировая болезнь печенисердечно-сосудистые заболеваниякардиоваскулярный риск

non-alcoholic fatty liver diseasecardiovascular diseasescardiovascular risk

Исследование проводится в рамках задания НИОК(Т)Р «Распространенность и факторы, ассоциированные с нарушениями костно-мышечного статуса, у пациентов молодого и среднего возраста с артериальной гипертензией и неалкогольной жировой болезнью печени в российской и белорусской популяциях» совместно с ФГБУ «НМИЦ ТПМ» Минздрава России. № гос. регистрации 20221914 от 27.12.2022.

References1

Maevskaya M.V., Kotovskaya Yu.V., Ivashkin V.T., Tkacheva O.N., Troshina E.A., Shestakova M.V., Breder V.V., Geyvandova N.I., Doshchitsin V.L., Dudinskaya E.N., Ershova E.V., Kodzoeva Kh.B., Komshilova K.A., Korochanskaya N.V., Mayorov A.Yu., Mishina E.E., Nadinskaia M.Yu., Nikitin I.G., Pogosova N.V., Tarzimanova A.I., Shamkhalova M.Sh. Nacionalnyj konsensus dlya vrachej po vedeniyu vzroslyh pacientov s nealkogolnoj zhirovoj bolezn’yu pecheni i ee osnovnymi komorbidnymi sostoyaniyami [The National Consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbidities]. Ter Arkhiv, 2022, vol. 94, no. 2, рр. 216–253. doi: 10.26442/00403660.2022.02.201363. (in Russian).

Younossi Z.M., Koenig A.B., Abdelatif D., et al. Global Epidemiology of Nonalcoho-lic Fatty Liver Disease-Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes. Hepatology. 2016, vol 64, no. 1, pp. 73-84. doi: 10.1002/hep.28431.

Drapkina O.M., Ivashkin V.T. Epidemiologicheskie osobennosti nealkogolnoj zhirovoj bolezni pecheni v rossii (rezultaty otkrytogo mnogocentrovogo prospektivnogo issledovaniya-nablyudeniya DIREG L 01903) [Epidemiologic features of non- alcoholic fatty liver disease in Russia (Results of open multicenter prospective observational study DIREG L 01903)]. Russ J Gastroenterol Hepatol Coloproctiol, 2014, vol. 24, no. 4, pp. 32–38. (in Russian).

Evstifeeva S.E., Shalnova S.A., Kutsenko V.A., Yarovaya E.V., Balanova Yu.A., Imaeva A.E., Kapustina A.V., Muromtseva G.A., Maksimov S.A., Karamnova N.S., Soplenkova A.G., Filichkina E.M., Viktorova I.A., Prishchepa N.N., Redko A.N., Yakushin S.S., Drapkina O.M. Rasprostranennost nealkogolnoj zhirovoj bolezni pecheni sredi naseleniya trudosposobnogo vozrasta: associacii s socialno-demograficheskimi pokazatelyami i povedencheskimi faktorami riska (DANNYE ESSE-RF-2) [Prevalence of non-alcoholic fatty liver disease among the working-age population: associations with socio-demographic indicators and behavioral risk factors (ESSE RF-2 data)]. Kardiovaskulyarnaya terapiya i profilaktika. 2022, vol. 21, no 9, pp. 40–49. doi: 10.15829/1728-8800-2022-3356 (in Russian).

Younossi Z.M., Stepanova M., Afendy M., et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol, 2011, vol. 9, no. 6, pp. 524–530. doi: 10.1016/j.cgh.2011.03.020.

Day C.P., James O.F. Steatohepatitis: a tale of two “hits”? Gastroenterology, 1998, vol. 114, pp. 842–845. doi: 10.1016/s0016-5085(98)70599-2.

Xian Y.X., Weng J.P., Xu F. MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy. Chin Med J. 2020, vol. 134, pp. 8 doi: 10.1097/ CM9.0000000000001263.

Wu Y., Zheng Q., Zou B., Yeo Y.H., Li X., Li J., et al. The epidemiology of NAFLD in Mainland China with analysis by adjusted gross regional domestic product: a meta-analysis. Hepatol Int, 2020, vol. 12, pp. 259–269. doi: 10.1007/s12072-020-10023-3.

Maev I.V., Andreev D.N., Kucheryavyy Yu.A. Prevalence of non-alcoholic fat disease liver in Russian Federation: meta-analysis. Consilium Medicum, 2023, vol. 25, no. 5, pp. 313–319. doi: 10.26442/20751753.2023.5.202155.

Le M.H., Yeo Y.H., Li X., et al. 2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol, 2022, vol. 20, no. 12, pp. 2809-2817. doi: 10.1097/HC9.0000000000000244.

Younossi Z.M., Golabi P., Paik J.M., et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology, 2023, vol. 77, no. 4, pp. 1335-1347. doi: 10.1097/HEP.0000000000000004.

Kotovskaya Yu.V. Non-alcoholic fatty liver disease and cardiovascular risks: A review. Consilium Medicum, 2023, vol. 25, no. 4, pp. 253–258. doi: 10.26442/20751753.2023.4.202275.

Rinella M.E., Lazarus J.V., Ratziu V., Francque S.M., Sanyal A.J., Kanwal, F., Romero D., et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023. doi: 10.1097/HEP.0000000000000520.

Eslam M., Sanyal A.J., George J., Sanyal A., Neuschwander-Tetri B., Tiribelli C., et al. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020, vol. 158, pp. 1999–2014. doi: 10.1053/j.gastro.2019.11.312.

Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020, vol. 7, pp. 202–209. doi: 10.1016/j.jhep.2020.03.039.

Pakhomova I.G., Knorring G.Yu. Nealkogolnaya zhirovaya bolezn’ pecheni i serdechno-sosudistaya patologiya: osobennosti vedeniya pacienta na klinicheskom primere [Non-alcoholic fatty liver disease and cardiovascular pathology: features of patient management on a clinical example]. Experimental Clin Gastroenterology, 2022, no. 9(205), pp. 290–297. doi: 10.31146/1682-8658-ecg-205-9-290-297. (in Russian).

Ivashkin V.T., Maevskaya M.V., Zharkova M.S., Kotovskaya Yu.V., Tkacheva O.N., Troshina E.A., Shestakova M.V., Maev I.V., Breder V.V., Gheivandova N.I., Doshchitsin V.L., Dudinskaya E.N., Ershova E.V., Kodzoeva Kh.B., Komshilova K.A., Korochanskaya N.V., Mayorov A.Yu., Mishina E.E., Nadinskaya M.Yu., Nikitin I.G., Pogosova N.V., Tarzimanova A.I., Shamkha-lova M.Sh. Klinicheskie rekomendacii Rossijskogo obshchestva po izucheniyu pecheni, Rossijskoj gastroenterologicheskoj associacii, Rossijskoj associacii endokrinologov, Rossijskoj associacii gerontologov i geriatrov i Nacionalnogo obshchestva profilakticheskoj kardiologii po diagnostike i lecheniyu nealkogolnoj zhirovoj bolezni pecheni [Clinical Practice Guidelines of the Russian Scientific Liver Society, Russian Gastroenterological Association, Russian Association of Endocrinologists, Russian Association of Gerontologists and Geriatricians and National Society for Preventive Cardiology on Diagnosis and Treatment of Non-Alcoholic Liver Disease]. Russ J Gastroenterol Hepatol Coloproctiol, 2022, vol. 32, no 4, pp. 104–140. doi: 10.22416/1382-4376-2022-32-4-104-140. (in Russian).

Pavlov Ch.S., Kuznetsova Е.A., Arslanyan M.G., Semenistaya M.Ch., Glushenkov D.V., Nikolenko V.N. Nealkogolnaya zhirovaya bolezn pecheni: sovremennye koncepcii etiologii, patogeneza, diagnostiki i lecheniya [Non-alcoholic fatty liver disease: modern concepts of etiology, pathogenesis]. Med Vestn Severnogo Kavkaza, 2017, vol. 12, no. 2, pp. 230-234. doi: 10.14300/mnnc.2017.1206.

Drapkina O.M., Yafarova A.A. Nealkogolnaya zhirovaya bolezn pecheni i serdechno-sosudistyj risk: sostoyanie problemy [Non-Alcoholic Fatty Liver Disease and Cardiovascular Risk: Scientific Problem State]. Rat Pharmacother Cardiology, 2017, vol. 13, no. 5, pp. 645-650. doi: 10.20996/1819-6446-2017-13-5-645-650. (in Russian).

Lambert J.E., Ramos-Roman M.A., Browning J.D., Parks E.J. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fat-ty liver disease. Gastroenterology, 2014, vol. 146, pp. 726–35. doi: 10.1053/j.gastro.2013.11.049.

Younossi Z. Global epidemiology of nonalcoholic fatty liver desease – Meta-analytic assessment of prevalence, incidence and outcomes. Hepatology. 2016, vol. 64, pp. 73–84. doi: 10.1002/hep.28431.

Zhou Y.Y., Zhou X.D., Wu S.J., Fan D.H., Van Poucke S., Chen Y.P., Fu S.W., Zheng M.H. Nonalcoholic fatty liver disease contributes to subclinical atherosclerosis: A syste- matic review and meta-analysis. Hepatol Commun, 2018, vol. 2, pp. 376–392. doi: 10.1002/hep4.115.

Mantovani A., Dauriz M., Sandri D., Bonapace S., Zoppini G., Tilg H., Byrne C.D., Targher G. Association between non-alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: An updated meta-analysis. Liver Int, 2019, vol. 39, pp. 758–769. doi: 10.1111/liv.14044.

Cai X., Zheng S., Liu Y., Zhang Y., Lu J., Huang Y. Nonalcoholic fatty liver disease is associated with increased risk of atrial fibrillation. Liver Int, 2020, vol. 40, pp. 1594–1600. doi: 10.1111/liv.14461.

Wijarnpreecha K., Lou S., Panjawatanan P., Cheungpasitporn W., Pungpapong S., Lukens F.J., Ungprasert P. Association between diastolic cardiac dysfunction and nonalcoholic fatty liver disease: a systematic review and meta-analysis. Dig Liver Dis, 2018, vol. 50, pp. 1166–1175. doi: 10.1016/j.dld.2018.09.004.

Cheungpasitporn W., Ungprasert P. Association between cardiac conduction defect and nonalcoholic fatty liver disease: a systematic review and meta-analysis. Ann Gastroenterol, 2020, vol. 33, pp. 661–666. doi: 10.20524/aog.2020.0535.

Di Minno M.N., Di Minno A., Ambrosino P., Songia P., Tremoli E., Poggio P. Aortic valve sclerosis as a marker of atherosclerosis: novel insights from hepatic steatosis. Int J Cardiol, 2016, vol. 217, pp. 1–6. doi: 10.1016/j.ijcard.2016.04.162.

Muzurović E., Peng C.C., Belanger M.J., Sanoudou D., Mikhailidis D.P., Mantzoros C.S. Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: a Review of Shared Cardiometabolic Risk Factors. Hypertension. 2022, vol. 79, no 7, pp. 1319-1326. doi: 10.1161/HYPERTENSIONAHA.122.17982.

Oikonomou D., Georgiopoulos G., Katsi V., Kourek C., Tsioufis C., Alexopoulou A., Koutli E., Tousoulis D. Non-alcoholic fatty liver disease and hypertension: coprevalent or correlated? Eur J Gastroenterol Hepatol. 2018, vol. 30, pp. 979–985. doi: 10.1097/MEG.0000000000001191.

Donati G., Stagni B., Piscaglia F., Venturoli N., Morselli-Labate A.M., Rasciti L., Bolondi L. Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance. Gut, 2004, vol. 53, no 7, pp. 1020-3. doi: 10.1136/gut.2003.027086.

Zhao Y.C., Zhao G.J., Chen Z., She Z.G., Cai J., Li H. Nonalcoholic Fatty Liver Disease: An Emerging Driver of Hypertension. Hypertension, 2020, vol. 75, no 2, pp. 275-284. doi: 10.1161/HYPERTENSIONAHA.119.13419.

Ma J., Hwang S.J., Pedley A., Massaro J.M., Hoffmann U., Chung R.T., Benjamin E.J., Levy D., Fox C.S., Long M.T. Bi-directional analysis between fatty liver and cardiovascular disease risk factors. J Hepatol, 2017, vol. 66, pp. 390–397. doi: 10.1016/j.jhep.2016.09.022.

Targher G., Bertolini L., Rodella S., Tessari R., Zenari L., Lippi G., Arcaro G. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care, 2007, vol. 30, no. 8, pp. 2119–2121. doi: 10.2337/dc07-0349.

Mahfood H.T., Hamdeh S., Kanmanthareddy A., Alla V.M. Nonalcoholic fatty liver disease and the risk of clinical cardiovascular events: A systematic review and meta-analysis. Diabetes Metab Syndr, 2017, vol. 11, no. 1, pp. 209-S216. doi: 10.1016/j.dsx.2016.12.033.

Targher G., Byrne C.D., Lonardo A., Zoppini G., Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. J Hepatol, 2016, vol. 65, no. 3, pp. 589–600. doi: 10.1016/j.jhep.2016.05.013.

The authors declare that there are no conflicts of interest present.